Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Sarcoma, Kaposi 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, Follicular 1 Lymphoma, B-Cell 1 Leukemia, Myeloid, Acute 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Hodgkin Disease 1 Hematologic Neoplasms 1 Colorectal Neoplasms 1 Anemia, Refractory, with Excess of Blasts 1

Interventions

Bevacizumab 112 Fluorouracil 98 Oxaliplatin 96 Leucovorin 96 Irinotecan 86 Capecitabine 73 Cetuximab 64 Panitumumab 42 pembrolizumab 38 regorafenib 28 Nivolumab 23 IFL protocol 22 Folfox protocol 21 trifluridine tipiracil drug combination 14 Radiotherapy 13 durvalumab 11 Gemcitabine 10 Celecoxib 10 tremelimumab 7 binimetinib 7 aflibercept 7 Drug Therapy 7 Disulfides 7 Cyclophosphamide 7 Trifluridine 6 Trastuzumab 6 Sunitinib 6 Paclitaxel 6 Immunoglobulin G 6 Colonoscopy 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Colorectal Neoplasms × Maraviroc × Clear all

NCT03274804 2022-06-07

PICCASSO

University Hospital Heidelberg

Phase 1 Completed

20 enrolled 12 charts

Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡